Adrenal cortical tumors and multiple endocrine neoplasia-related syndromes

Minerva Endocrinologica

Volumn 34, Issue 2, 2009, Pages 123-135

  Haase, M ^a   Willenberg, H S ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Adrenal gland neoplasms; Aldosterone; Hypertension; Multiple endocrine neoplasia

Indexed keywords

CISPLATIN; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; METHIONINE; MITOTANE; STREPTOZOCIN; SUNITINIB; TARIQUIDAR;

ADENOMATOSIS; ADRENAL CORTEX CARCINOMA; ADRENAL CORTEX TUMOR; ALBRIGHT SYNDROME; CANCER DIAGNOSIS; CANCER GENETICS; CANCER THERAPY; CARCINOGENESIS; CARNEY COMPLEX; CLINICAL TRIAL; DISEASE ASSOCIATION; FAMILIAL ADENOMATOSIS POLYPOSIS COLI; FAMILIAL CANCER; HUMAN; HYPERALDOSTERONISM; MULTIPLE ENDOCRINE NEOPLASIA; REVIEW; BECKWITH WIEDEMANN SYNDROME; COLON POLYPOSIS; CONGENITAL ADRENAL HYPERPLASIA; GENETICS; HEART TUMOR; MUTATION; MYXOMA; PIGMENT DISORDER;

ADENOMATOUS POLYPOSIS COLI; ADRENAL CORTEX NEOPLASMS; ADRENAL HYPERPLASIA, CONGENITAL; BECKWITH-WIEDEMANN SYNDROME; FIBROUS DYSPLASIA, POLYOSTOTIC; HEART NEOPLASMS; HUMANS; HYPERALDOSTERONISM; LI-FRAUMENI SYNDROME; MULTIPLE ENDOCRINE NEOPLASIA; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; MUTATION; MYXOMA; PIGMENTATION DISORDERS;

EID: 70349758565     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Review

References (101)

1. Stratakis CA, Boikos SA. Genetics of adrenal tumors associated with Cushing's syndrome: a new classification for bilateral adrenocortical hyperplasias. Nat Clin Pract Endocrinol Metab 2007;3:748-57.
2. Robinson-White A, Meoli E, Stergiopoulos S, Horvath A, Boikos S, Bossis I et al. PRKAR1A Mutations and protein kinase A interactions with other signaling pathways in the adrenal cortex. J Clin Endocrinol Metab 2006;91:2380-8.
3. Winnay JN, Hammer GD. Adrenocorticotropic hormone-mediated signaling cascades coordinate a cyclic pattern of steroidogenic factor 1-dependent transcriptional activation. Mol Endocrinol 2006;20:147-66.
4. 2 to urinary potassium (SUSPPUP) ratio in primary aldosteronism. Eur J Clin Invest 2009;39:43-50.
5. Forest MG. Recent advances in the diagnosis and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Hum Reprod Update 2004;10:469-85.
6. O'Bryan RM, Smith RW Jr, Fine G, Mellinger RC. Congenital adrenocortical hyperplasia with Cushing's syndrome. JAMA 1964;187:257-61.
7. White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000;21:245-91.
8. New MI. An update of congenital adrenal hyperplasia. Ann N Y Acad Sci 2004;1038:14-43
9. Merke DP, Bornstein SR. Congenital adrenal hyperplasia. Lancet 2005;365:2125-36.
10. Bongiovanni AM. The adrenogenital syndrome with deficiency of 3beta-hydroxysteroid dehydrogenase. J Clin Invest 1962;41:2086.
11. Rhéaume E, Simard J, Morel Y, Mebarki F, Zachmann M, Forest MG et al. Congenital adrenal hyperplasia due to point mutations in the type II 3beta-hydroxysteroid dehydrogenase gene. Nature Genet 1992;1:239-45.
12. Eberlein WR, Bongiovanni AM. Plasma and urinary corticosteroids in the hypertensive form of congenital adrenal hyperplasia. J Biol Chem 1956;223:85-94.
13. Biglieri EG, Herron MA, Brust N. 17-hydroxylation deficiency in man. J Clin Invest 1966;45:1946-54.
14. Ghayee HK, Auchus RJ. Basic concepts and recent developments in human steroid hormone biosynthesis. Rev Endocr Metab Disord 2007;8:289-300.
15. Flück CE, Tajima T, Pandey AV, Arlt W, Okuhara K, Verge CF et al. Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat Genet 2004;36:228-30.
16. Carney JA, Gordon H, Carpenter PC, Shenoy BV, Go VL. The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine (Baltimore) 1985;64:270-83.
17. Casey M, Mah C, Merliss AD, Kirschner LS, Taymans SE, Denio AE et al. Identification of a novel genetic locus for familial cardiac myxomas and Carney complex. Circulation 1998;98:2560-6.
18. Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, Cho YS et al. Mutations of the gene encoding the protein kinase A type I- regulatory subunit in patients with the Carney complex. Nat Genet 2000;26:89-92.
19. Stratakis CA, Kirschner LS, Carney JA. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab 2001;86:4041-6.
20. Stratakis CA, Sarlis N, Kirschner LS, Carney JA, Doppman JL, Nieman LK et al. Paradoxical response to dexamethasone in the diagnosis of primary pigmented nodular adrenocortical disease. Ann Intern Med 1999;131:585-91.
21. Rockall AG, Babar SA, Sohaib SA, Isidori AM, Diaz-Cano S, Monson JP et al. CT and MR imaging of the adrenal glands in ACTH-independent cushing syndrome. Radiographics 2004;24:435-52.
22. Horvath A, Boikos S, Giatzakis C, Robinson-White A, Groussin L, Griffin KJ et al. A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11 A4 (PDE11A) in individuals with adrenocortical hyperplasia. Nat Genet 2006;38:794-800. (Pubitemid 43980600)
23. Horvath A, Mericq V, Stratakis CA Mutation in PDE8B, a cyclic AMP-specific phosphodiesterase in adrenal hyperplasia. N Engl J Med 2008;358:750-2.
24. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 1991;325:1688-95.
25. Schwindinger WF, Francomano CA, Levine MA. Identification of a mutation in the gene encoding the alpha subunit of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome. Proc Natl Acad Sci USA 1992;89:5152-6.
26. Shenker A, Weinstein LS, Moran A, Pescovitz OH, Charest NJ, Boney CM et al. Severe endocrine and nonendocrine manifestations of the McCune-Albright syndrome associated with activating mutations of stimulatory G protein GS. J Pediatr 1993;123:509-18. (Pubitemid 23287518)
27. Lumbroso S, Paris F, Sultan C; European Collaborative Study. Activating Gsalpha mutations: analysis of 113 patients with signs of McCune-Albright syndrome - a European Collaborative Study. J Clin Endocrinol Metab 2004;89:2107-13. (Pubitemid 38619838)
28. Dumitrescu CE, Collins MT McCune-Albright syndrome. Orphanet J Rare Dis 2008;3:12.
29. Fragoso MC, Domenice S, Latronico AC, Martin RM, Pereira MA, Zerbini MC et al. Cushing's syndrome secondary to adrenocorticotropin-independent macronodular adrenocortical hyperplasia due to activating mutations of GNAS1 gene. J Clin Endocrinol Metab 2003;88:2147-51. (Pubitemid 36549891)
30. Kirk JM, Brain CE, Carson DJ, Hyde JC, Grant DB. Cushing's syndrome caused by nodular adrenal hyperplasia in children with McCune-Albright syndrome. J Pediatr 1999;134:789-92.
31. Collins MT, Kushner H, Reynolds JC, Chebli C, Kelly MH, Gupta A et al. An instrument to measure skeletal burden and predict functional outcome in fibrous dysplasia of bone. J Bone Miner Res 2005;20:219-26.
32. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997;276:404-7.
33. Agarwal SK, Mateo CM, Marx SJ. Rare germline mutations in cyclin-dependent kinase inhibitor genes in MEN1 and related states. J Clin Endocrinol Metab 2009 [Epub ahead of print].
34. Schussheim DH, Skarulis MC, Agarwal SK, Simonds WF, Burns AL, Spiegel AM et al. Multiple endocrine neoplasia type 1: new clinical and basic findings. Trends Endocrinol Metab. 2001;12:173-8.
35. Waldmann J, Bartsch DK, Kann PH, Fendrich V, Rothmund M, Langer P. Adrenal involvement in multiple endocrine neoplasia type 1: results of 7 years prospective screening. Langenbecks Arch Surg 2007;392:437-43.
36. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86:5658-71.
37. Ellard S, Hattersley AT, Brewer CM, Vaidya B. Detection of an MEN1 gene mutation depends on clinical features and supports current referral criteria for diagnostic molecular genetic testing. Clin Endocrinol 2005;62:169-75.
38. Devic A, Bussy MM. Un cas de polypose adénomateuse: Generalisé e à tout l'intestin. Arch Mal Appar Dig 1912; 6:278-89.
39. Gardner EJ. A genetic and clinical study of intestinal polyposis, a predisposing factor for carcinoma of the colon and rectum. Am J Hum Genet 1951;3:167-76.
40. Seki M, Tanaka K, Kikuchi-Yanoshita R, Konishi M, Fukunari H et al. Loss of normal allele of the APC gene in an adrenocortical carcinoma from a patient with familial adenomatous polyposis. Hum Genet 1992;89:298-300.
41. Yamakita N, Murai T, Ito Y, Miura K, Ikeda T, Miyamoto K et al. Adrenocorticotropin-independent macronodular adrenocortical hyperplasia associated with multiple colon adenomas/carcinomas which showed a point mutation in the APC gene. Intern Med 1997;36:536-42.
42. Kartheuser A, Walon C, West S, Breukel C, Detry R, Gribomont AC, et al. Familial adenomatous polyposis associated with multiple adrenal adenomas in a patient with a rare 3′ APC mutation. J Med Genet 1999;36:65-7.
43. Beuschlein F, Reincke M, Königer M, D'Orazio D, Dobbie Z, Rump LC. Cortisol-producing adrenal adenoma - a new manifestation of Gardner's syndrome. Endocr Res 2000;26:783-90.
44. Alexander GL, Thompson GB, Schwartz DA. Primary aldosteronism in a patient with familial adenomatous polyposis. Mayo Clin Proc 2000; 75:636-7.
45. Marchesa P, Fazio VW, Church JM, McGannon E. Adrenal masses in patients with familial adenomatous polyposis. Dis Colon Rectum 1997;40:1023-8. (Pubitemid 27377577)
46. Smith TG, Clark SK, Katz DE, Reznek RH, Phillips RK. Adrenal masses are associated with familial adenomatous polyposis. Dis Colon Rectum 2000; 43:1739-42.
47. Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev 2004;25:309-40. (Pubitemid 38528713)
48. Groen EJ, Roos A, Muntinghe FL, Enting RH, de Vries J, Kleibeuker JH et al. Extra-intestinal manifestations of familial adenomatous polyposis. Ann Surg Oncol 2008;15:2439-50.
49. Stilberg P, Santesson M, Ekeblad S, Lejonklou MH, Skogseid B. Recognizing genes differentially regulated in vitro by the multiple endocrine neoplasia type 1 (MEN1) gene, using RNA interference and oligonucleotide microarrays. Surgery 2006;140:921-31. (Pubitemid 44937376)
50. Chen G, A J, Wang M, Farley S, Lee LY, Lee LC, Sawicki MP. Menin promotes the Wnt signaling pathway in pancreatic endocrine cells. Mol Cancer Res 2008;6:1894-907.
51. Bertherat J, Groussin L, Bertagna X Mechanisms of disease: adrenocortical tumors - molecular advances and clinical perspectives. Nat Clin Pract Endocrinol Metab 2006;2:632-41. (Pubitemid 44691299)
52. Schinner S, Willenberg HS, Schott M, Scherbaum WA. Pathophysiological aspects of Wnt-signalling in endocrine disease. Eur J Endocrinol 2009 [Epub ahead of printing].
53. Tissier F, Cavard C, Groussin L, Perlemoine K, Fumey G, Hagnere AM et al. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res 2005;65:7622-7. (Pubitemid 41297234)
54. Tadjine M, Lampron A, Ouadi L, Horvath A, Stratakis CA, Bourdeau I. Detection of somatic beta-catenin mutations in primary pigmented nodular adrenocortical disease (PPNAD). Clin Endocrinol 2008;69:367-73.
55. Iliopoulos D, Bimpaki EI, Nesterova M, Stratakis CA. MicroRNA signature of primary pigmented nodular adrenocortical disease: clinical correlations and regulation of Wnt signaling. Cancer Res 2009;69:3278-82.
56. Sutherland DJ, Ruse JL, Laidlaw JC. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can Med Assoc J 1966;95:1109-19.
57. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel JM. A chimaeric 11beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992;355:262-5.
58. Litchfield WR, New MI, Coolidge C, Lifton RP, Dluhy RG. Evaluation of the dexamethasone suppression test for the diagnosis of glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 1997;82:3570-3. (Pubitemid 27509338)
59. Jonsson JR, Klemm SA, Tunny TJ, Stowasser M, Gordon RD. A new genetic test for familial hyperaldosteronism type I aids in the detection of curable hypertension. Biochem Biophys Res Commun 1995;207:565-71.
60. MacConnachie AA, Kelly KF, McNamara A, Loughlin S, Gates LJ, Inglis GC et al. Rapid diagnosis and identification of crossover sites in patients with glucocorticoid remediable aldosteronism. J Clin Endocrinol Metab 1998;83:4328-31. (Pubitemid 29100130)
61. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M et al. for the Endocrine Society. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008;93:3266-81.
62. Gordon RD. Primary aldosteronism. J Endocrinol Invest 1995;18:495-511.
63. Torpy DJ, Gordon RD, Lin JP, Huggard PR, Taymans SE, Stowasser M et al. Familial hyperaldosteronism type II: description of a large kindred and exclusion of the aldosterone synthase (CYP11B2) gene. J Clin Endocrinol Metab 1998;83: 3214-8. (Pubitemid 28500961)
64. Geller DS, Zhang J, Wisgerhof MV, Shackleton C, Kashgarian M, Lifton RP. A novel form of human mendelian hypertension featuring nonglucocorticoid- remediable aldosteronism. J Clin Endocrinol Metab 2008;93:3117-23.
65. Beckwith JB Extreme cytomegaly of the adrenal fetal cortex, omphalocele, hyperplasia of kidneys and pancreas, and Leydig-cell hyperplasia: another syndrome? 11th Annual Meeting of Western Society for Pediatric Research, Los Angeles 1963.
66. Wiedemann HR. Familial malformation complex with umbilical hernia and macroglossia - a new syndrome? J Genet Hum 1964;13:223-32.
67. Daugbjerg P, Everberg G. A case of Beckwith-Wiedemann syndrome with conductive hearing loss. Acta Paediatr Scand 1984;73:408-10.
68. Gianotten J, van der Veen F, Alders M, Leschot NJ, Tanck MW, Land JA et al. Chromosomal region 11p15 is associated with male factor subfertility. Mol Hum Reprod 2003;9:587-92. (Pubitemid 37220818)
69. Cohen MM Jr. Beckwith-Wiedemann syndrome: historical, clinicopathological, and etiopathogenetic perspectives. Pediatr Dev Pathol 2005;8:287-304.
70. Ping AJ, Reeve AE, Law DJ, Young MR, Boehnke M, Feinberg AP. Genetic linkage of Beckwith-Wiedemann syndrome to 11p15. Am J Hum Genet 1989;44:720-3. (Pubitemid 19119984)
71. Koufos A, Grundy P, Morgan K, Aleck KA, Hadro T, Lampkin BC et al. Familial Wiedemann-Beckwith syndrome and a second Wilms tumor locus both map to 11p15.5. Am J Hum Genet 1989;44:711-9. (Pubitemid 19119983)
72. Hao Y, Crenshaw T, Moulton T, Newcomb E, Tycko B. Tumour-suppressor activity of H19 RNA Nature 1993;365:764-7.
73. Fottner Ch, Hoeflich A, Wolf E, Weber MM. Role of the insulin-like growth factor system in adrenocortical growth control and carcinogenesis. Horm Metab Res 2004;36:397-405. (Pubitemid 38932097)
74. Kirschner LS. Signaling pathways in adrenocortical cancer. Ann NY Acad Sci 2002;968:222-39.
75. Weksberg R, Shuman C, Smith AC. Beckwith-Wiedemann syndrome. Am J Med Genet C Semin Med Genet 2005;137C:12-23.
76. Greer KJ, Kirkpatrick SJ, Weksberg R, Pauli RM. Beckwith-Wiedemann syndrome in adults: observations from one family and recommendations for care. Am J Med Genet A 2008;146A:1707-12. (Pubitemid 351975481)
77. Tan TY, Amor DJ. Tumour surveillance in Beckwith-Wiedemann syndrome and hemihyperplasia: a critical review of the evidence and suggested guidelines for local practice. J Paediatr Child Health 2006;42:486-90.
78. Li FP, Fraumeni JF Jr, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988;48:5358-62.
79. Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 1994;54:1298-304.
80. Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999;286:2528-31.
81. Bachinski LL, Olufemi SE, Zhou X, Wu CC, Yip L, Shete S et al. Genetic mapping of a third Li-Fraumeni syndrome predisposition locus to human chromosome 1q23. Cancer Res 2005;65:427-31.
82. Peña CS, Boland GW, Hahn PF, Lee MJ, Mueller PR. Characterization of indeterminate (lipid-poor) adrenal masses: use of washout characteristics at contrast-enhanced CT. Radiology 2000;217:798-802.
83. Boland GW, Blake MA, Hahn PF, Mayo-Smith WW. Incidental adrenal lesions: principles, techniques, and algorithms for imaging characterization. Radiology 2008;249:756-75.
84. Zech CJ, Weiss M, Schoenberg SO, Herrmann KA, Helmberger T, Reiser MF. Value of various imaging modalities for diagnostic work-up of tumors of the adrenal gland. Radiologe 2003;43:284-92.
85. Bauditz J, Quinkler M, Beyersdorff D, Wermke W. Improved detection of hepatic metastases of adrenocortical cancer by contrast-enhanced ultrasound. Oncol Rep 2008;19:1135-9.
86. Hahner S, Stuermer A, Kreissl M, Reiners C, Fassnacht M, Haenscheid H et al. [123 I]Iodometomidate for molecular imaging of adrenocortical cytochrome P450 family HB enzymes. J Clin Endocrinol Metab 2008;93:2358-65.
87. Lee JE, Berger DH, el-Naggar AK, Hickey RC, Vassilopoulou-Sellin R, Gagel RF et al. Surgical management, DNA content, and patient survival in adrenal cortical carcinoma. Surgery 1995;118:1090-8.
88. Kopf D, Goretzki PE, Lehnert H. Clinical management of malignant adrenal tumors. J Cancer Res Clin Oncol 2001;127:143-55.
89. Willenberg HS, Zschucke D, Bornstein SR. Adrenal gland tumors. Internist 2007;48:971-86.
90. Fassnacht M, Hahner S, Polat B, Koschker AC, Kenn W, Flentje M et al. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab 2006;91:4501-4.
91. Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 2007;356:2372-80.
92. Patalano A, Brancato V, Mantero F. Adrenocortical cancer treatment. Horm Res 2009;71(Suppl 1):99-104.
93. Allolio B, Fassnacht M. Clinical review: Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 2006;91:2027-37.
94. First International Randomized trial in locally advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)", [cited 2009 April 28]. Available from: www.firm-act.org.
95. Quinkler M, Hahner S, Wortmann S, Johanssen S, Adam P, Ritter C et al. Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J Clin Endocrinol Metab 2008;93:2057-62.
96. Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F et al. for the German Adrenocortical Carcinoma Registry Group; European Network for the Study of Adrenal Tumors. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer 2009;115:243-50.
97. Schorr I, Rathnam P, Saxena BB, Ney RL. Multiple specific hormone receptors in the adenylate cyclase of an adrenocortical carcinoma. J Biol Chem 1971;246:5806-11.
98. Lacroix A, N'Diaye N, Tremblay J, Hamet P. Ectopic and abnormal hormone receptors in adrenal Cushing's syndrome. Endocr Rev 2001;22:75-110. (Pubitemid 32187804)
99. Swords FM, Noon LA, King PJ, Clark AJ. Constitutive activation of the human ACTH receptor resulting from a synergistic interaction between two naturally occurring missense mutations in the MC2R gene. Mol Cell Endocrinol 2004;213:149-54.
100. Swords FM, Baig A, Malchoff DM, Malchoff CD, Thorner MO, King PJ et al. Impaired desensitization of a mutant adrenocorticotropin receptor associated with apparent constitutive activity. Mol Endocrinol 2002;16:2746-53.
101. th Annual Meeting; 2008 June 15; San Francisco, CA, USA. Chevy Chase, MD, USA: The Endocrine Society Press; 2008. p. 303.